Clinical Trial Update: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) [Phase 3]

View source ↗

Summary

A Phase 3 trial of donanemab (LY3002813) in participants with preclinical Alzheimer’s disease is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Donanemab (donanemab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING